Literature DB >> 8916965

Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax.

M Lisovsky1, Z Estrov, X Zhang, U Consoli, G Sanchez-Williams, V Snell, R Munker, A Goodacre, V Savchenko, M Andreeff.   

Abstract

Flt3/flk-2 ligand (flt3-L) is a potent costimulator of normal bone marrow (BM) myeloid progenitors. Flt3-L is produced by BM stromal cells and its receptor is expressed in the majority of acute myeloid leukemia (AML) cases. Therefore, flt3-L may play a role in the paracrine and/or autocrine loops sustaining leukemic cell growth. We evaluated the effects of recombinant human flt3-L on proliferation, apoptosis, and Bcl-2 and Bax expression in primary AML cells and compared them with those of stem cell factor (SCF). Mononuclear BM cells from patients with newly diagnosed AML were cultured in serum-free conditions with flt3-L, SCF, granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage-colony-stimulating factor (GM-CSF) alone and in combination. In 9 of 10 samples, flt3-L significantly increased [3H]thymidine uptake (geometric mean stimulation index, 7.5; range, 2.4 to 41.5). Flt3-L also increased the number of AML blast colonies by 126% (range, 61% to 181%). In these 9 samples, flt3-L significantly enhanced the proliferative response triggered by G-CSF or GM-CSF. Flt3-L prevented apoptosis in AML blasts. It reduced the number of apoptotic cells by 36% +/- 3.9% compared with control cultures. Combining flt3-L with G-CSF or GM-CSF doubled the antiapoptotic effect. Cellular Bcl-2 and Bax levels were determined separately for apoptotic and nonapoptotic cells by flow cytometry. Cells undergoing spontaneous apoptosis had low Bcl-2 and high Bax levels, whereas nonapoptotic cells had high Bcl-2 and low Bax levels. Flt3-L alone or in combination with G-CSF or GM-CSF did not upregulate Bcl-2. However, Bax expression decreased in viable cells in the presence of these cytokines and the lowest level was achieved when a combination of flt3 and GM-CSF was used. Proliferative and viability effects of flt3-L were similar to those of SCF. Our results demonstrate that flt3-L acts as a stimulatory factor for primary AML cells. The antiapoptotic effects of flt3-L or its combinations with G-CSF or GM-CSF correlate with their ability to prevent upregulation of Bax.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8916965

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  Acute myeloid leukemia with normal cytogenetics.

Authors:  Raya Mawad; Elihu H Estey
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

2.  Overcoming adaptive therapy resistance in AML by targeting immune response pathways.

Authors:  Katelyn Melgar; Morgan M Walker; LaQuita M Jones; Lyndsey C Bolanos; Kathleen Hueneman; Mark Wunderlich; Jian-Kang Jiang; Kelli M Wilson; Xiaohu Zhang; Patrick Sutter; Amy Wang; Xin Xu; Kwangmin Choi; Gregory Tawa; Donald Lorimer; Jan Abendroth; Eric O'Brien; Scott B Hoyt; Ellin Berman; Christopher A Famulare; James C Mulloy; Ross L Levine; John P Perentesis; Craig J Thomas; Daniel T Starczynowski
Journal:  Sci Transl Med       Date:  2019-09-04       Impact factor: 17.956

Review 3.  FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms.

Authors:  Baku Acharya; Debasmita Saha; Daniel Armstrong; Naga Rajiv Lakkaniga; Brendan Frett
Journal:  RSC Med Chem       Date:  2022-05-23

Review 4.  Flt3 in acute myelogenous leukemia: biology, prognosis, and therapeutic implications.

Authors:  Ioannis A Voutsadakis
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

5.  Serine-70 phosphorylated Bcl-2 prevents oxidative stress-induced DNA damage by modulating the mitochondrial redox metabolism.

Authors:  Stephen Jun Fei Chong; Kartini Iskandar; Jolin Xiao Hui Lai; Jianhua Qu; Deepika Raman; Rebecca Valentin; Charles Herbaux; Mary Collins; Ivan Cherh Chiet Low; Thomas Loh; Matthew Davids; Shazib Pervaiz
Journal:  Nucleic Acids Res       Date:  2020-12-16       Impact factor: 16.971

6.  Further activation of FLT3 mutants by FLT3 ligand.

Authors:  R Zheng; E Bailey; B Nguyen; X Yang; O Piloto; M Levis; D Small
Journal:  Oncogene       Date:  2011-04-25       Impact factor: 9.867

7.  Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo.

Authors:  Nicole D Vincelette; Husheng Ding; Amelia M Huehls; Karen S Flatten; Rebecca L Kelly; Mira A Kohorst; Jonathan Webster; Allan D Hess; Keith W Pratz; Larry M Karnitz; Scott H Kaufmann
Journal:  Sci Rep       Date:  2019-03-05       Impact factor: 4.379

8.  FMS-Related Tyrosine Kinase 3 Ligand Promotes Radioresistance in Esophageal Squamous Cell Carcinoma.

Authors:  Zuoquan Zhu; Jiahang Song; Junjie Gu; Bing Xu; Xinchen Sun; Shu Zhang
Journal:  Front Pharmacol       Date:  2021-05-10       Impact factor: 5.810

9.  Angiopoietin-like protein 3 promotes preservation of stemness during ex vivo expansion of murine hematopoietic stem cells.

Authors:  Elnaz Farahbakhshian; Monique M Verstegen; Trudi P Visser; Sima Kheradmandkia; Dirk Geerts; Shazia Arshad; Noveen Riaz; Frank Grosveld; Niek P van Til; Jules P P Meijerink
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

10.  IL1RAP potentiates multiple oncogenic signaling pathways in AML.

Authors:  Kelly Mitchell; Laura Barreyro; Tihomira I Todorova; Samuel J Taylor; Iléana Antony-Debré; Swathi-Rao Narayanagari; Luis A Carvajal; Joana Leite; Zubair Piperdi; Gopichand Pendurti; Ioannis Mantzaris; Elisabeth Paietta; Amit Verma; Kira Gritsman; Ulrich Steidl
Journal:  J Exp Med       Date:  2018-05-17       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.